ANDA Approvals: Is FDA Productivity Boost Permanent?
This article was originally published in The Pink Sheet Daily
Fourth consecutive month of strong results suggests generic review function is back on track.
You may also be interested in...
Generic drug user fee reauthorization talks remain on schedule and are expected to last about four months.
Demand-related shortages are a relatively new problem, but the FDA maintains their tools can prevent or end them.
FDA Commissioner Robert Califf says mentioning China helps increase congressional support.